Published online October 2, 2006
PEDIATRICS Vol. 118 No. 5 November 2006, pp. e1563-e1568 (doi:10.1542/peds.2006-0904)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Filler, G.
Right arrow Articles by Christians, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Filler, G.
Right arrow Articles by Christians, U.
Related Collections
Right arrow Therapeutics & Toxicology

EXPERIENCE & REASON

Pharmacokinetics of Pyridostigmine in a Child With Postural Tachycardia Syndrome

Guido Filler, MD, PhDa, Robert M. Gow, MB, BSa, Renisha Nadarajaha, Pierre Jacob, MDa, Gillian Johnson, MDb, Yan-Ling Zhang, PhDb and Uwe Christians, MD, PhDb

a Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada
b Clinical Research and Development, Department of Anesthesiology, University of Colorado Health Sciences Center, Denver, Colorado

ABSTRACT

Pyridostigmine has been proposed for the treatment of postural orthostatic tachycardia syndrome in adults at a dose of 60 mg twice daily, but no dosing recommendation exists for children. With the approval of our local ethics board, we tested the pharmacokinetics of pyridostigmine in 6 children with myasthenia and a pediatric index patient with severe postural orthostatic tachycardia syndrome whose condition failed all conventional therapy and who had developed significant postural hypertension. Pyridostigmine was quantified by using a validated, semiautomated, and specific high-performance liquid chromatography/tandem mass spectrometry assay in combination with online column-switching extraction and turbo electrospray ionization. The patient with postural orthostatic tachycardia syndrome showed a dose-dependent favorable response to oral pyridostigmine. Pharmacokinetic evaluation revealed a short half-life of 2.29 hours, similar to the 2.0 ± 0.63 hours in the patients with myasthenia. The patient with postural orthostatic tachycardia syndrome has subsequently been treated at a dose of 45 mg in the morning, 30 mg at lunchtime, and 15 mg at bedtime; after 9 months, there has been persistent positive effect and without additional blood pressure medication. No major adverse effects occurred. Pyridostigmine has been a safe and effective treatment modality for this child with postural orthostatic tachycardia syndrome. The short half-life suggests that dosing 3 times per day is preferable.

Key Words: tachycardia • acetylcholine • nervous system • autonomic • pharmacokinetics • children

Abbreviations: POTS, postural orthostatic tachycardia syndrome • HPLC, high-performance liquid chromatography • LC/LC-MS/MS, high-performance liquid chromatography/tandem mass spectrometry assay in combination with online column-switching extraction and turbo electrospray ionization • AUC, area under the time-concentration curve • MRT, mean residence time • Cmax, maximum concentration • tmax, time to maximum concentration

Accepted Jun 5, 2006.




This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
B. J Gales and M. A Gales
Pyridostigmine in the Treatment of Orthostatic Intolerance
Ann. Pharmacother., February 1, 2007; 41(2): 314 - 318.
[Abstract] [Full Text] [PDF]